Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.
Martins TA, Kaymak D, Tatari N, Gerster F, Hogan S, Ritz MF, Sabatino V, Wieboldt R, Bartoszek EM, McDaid M, Gerber A, Buck A, Beshirova A, Heider A, Shekarian T, Mohamed H, Etter MM, Schmassmann P, Abel I, Boulay JL, Saito Y, Mariani L, Guzman R, Snijder B, Weiss T, Läubli H, Hutter G. Martins TA, et al. Among authors: schmassmann p. Nat Commun. 2024 Nov 9;15(1):9718. doi: 10.1038/s41467-024-54129-w. Nat Commun. 2024. PMID: 39521782 Free PMC article.
Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse.
Shekarian T, Ritz MF, Hogan S, Martins TA, Schmassmann P, Gerber A, Roux J, Kaymak D, Durano C, Burger B, Matter M, Hutter G. Shekarian T, et al. Among authors: schmassmann p. J Neuropathol Exp Neurol. 2024 Oct 18:nlae108. doi: 10.1093/jnen/nlae108. Online ahead of print. J Neuropathol Exp Neurol. 2024. PMID: 39423857
Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma.
Schmassmann P, Roux J, Buck A, Tatari N, Hogan S, Wang J, Rodrigues Mantuano N, Wieboldt R, Lee S, Snijder B, Kaymak D, Martins TA, Ritz MF, Shekarian T, McDaid M, Weller M, Weiss T, Läubli H, Hutter G. Schmassmann P, et al. Sci Transl Med. 2023 Jul 19;15(705):eadf5302. doi: 10.1126/scitranslmed.adf5302. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467314
Immunotherapy of glioblastoma explants induces interferon-γ responses and spatial immune cell rearrangements in tumor center, but not periphery.
Shekarian T, Zinner CP, Bartoszek EM, Duchemin W, Wachnowicz AT, Hogan S, Etter MM, Flammer J, Paganetti C, Martins TA, Schmassmann P, Zanganeh S, Le Goff F, Muraro MG, Ritz MF, Phillips D, Bhate SS, Barlow GL, Nolan GP, Schürch CM, Hutter G. Shekarian T, et al. Among authors: schmassmann p. Sci Adv. 2022 Jul;8(26):eabn9440. doi: 10.1126/sciadv.abn9440. Epub 2022 Jul 1. Sci Adv. 2022. PMID: 35776791 Free PMC article.
Microglia-Centered Combinatorial Strategies Against Glioblastoma.
Martins TA, Schmassmann P, Shekarian T, Boulay JL, Ritz MF, Zanganeh S, Vom Berg J, Hutter G. Martins TA, et al. Among authors: schmassmann p. Front Immunol. 2020 Sep 29;11:571951. doi: 10.3389/fimmu.2020.571951. eCollection 2020. Front Immunol. 2020. PMID: 33117364 Free PMC article. Review.
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer.
Tiede S, Meyer-Schaller N, Kalathur RKR, Ivanek R, Fagiani E, Schmassmann P, Stillhard P, Häfliger S, Kraut N, Schweifer N, Waizenegger IC, Bill R, Christofori G. Tiede S, et al. Among authors: schmassmann p. Oncogenesis. 2018 Sep 20;7(9):73. doi: 10.1038/s41389-018-0083-1. Oncogenesis. 2018. PMID: 30237500 Free PMC article.